HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study

Sarcopenia and treatment-related muscle loss are associated with increased toxicity and reduced resilience in cancer patients. HyperSight™ cone-beam CT (CBCT) provides improved soft-tissue contrast compared with conventional CBCT and may enable reliable longitudinal skeletal-muscle monitoring during...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Siefert, Victor (Auteur) , Bettenhausen, Joana van (Auteur) , Bicu, Alicia Simone (Auteur) , Schmidt, Ralf (Auteur) , Willam, Marvin (Auteur) , Eckl, Miriam (Auteur) , Stieler, Florian (Auteur) , Ehmann, Michael (Auteur) , Bürgy, Daniel (Auteur) , Fleckenstein, Jens (Auteur) , Beuthien-Baumann, Bettina (Auteur) , Schlemmer, Heinz-Peter (Auteur) , Froelich, Matthias F. (Auteur) , Schönberg, Stefan (Auteur) , Giordano, Frank Anton (Auteur) , Boda-Heggemann, Judit (Auteur) , Dreher, Constantin (Auteur)
Format: Article (Journal)
Langue:anglais
Publié: May 2026
In: Radiation oncology
Year: 2026, Volume: 21, Pages: 1-13
ISSN:1748-717X
DOI:10.1186/s13014-026-02856-3
Accès en ligne:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13014-026-02856-3
Accéder au texte intégral
Notes sur l'auteur:Victor Siefert, Joana V. Bettenhausen, Alicia S. Bicu, Ralf Schmidt, Marvin Willam, Miriam Eckl, Florian Stieler, Michael Ehmann, Daniel Buergy, Jens Fleckenstein, Bettina Beuthien-Baumann, Heinz-Peter Schlemmer, Matthias F. Froelich, Stefan O. Schoenberg, Frank A. Giordano, Judit Boda-Heggemann and Constantin Dreher
Description
Résumé:Sarcopenia and treatment-related muscle loss are associated with increased toxicity and reduced resilience in cancer patients. HyperSight™ cone-beam CT (CBCT) provides improved soft-tissue contrast compared with conventional CBCT and may enable reliable longitudinal skeletal-muscle monitoring during image-guided radiotherapy (IGRT). This study evaluated the feasibility of HyperSight™ CBCT-based muscle assessment in prostate cancer patients and explored the clinical relevance of intratreatment muscle decline.
Description:Im Titel ist TM hochgestellt
Online veröffentlicht: 29. Mai 2026
Gesehen am 11.06.2026
Description matérielle:Online Resource
ISSN:1748-717X
DOI:10.1186/s13014-026-02856-3